Introduction
Optic nerve hypoplasia (ONH), with a prevalence of 10.9 per 100,000, has been recognized over the past 30 years as a major cause of congenital blindness [1] [2] [3] . It rarely occurs in isolation, but more commonly presents with a number of systemic co-morbidities thought to be related to hypothalamic dysfunction [4] [5] [6] [7] [8] . The most common of these is hypopituitarism which may cause significant morbidity in this population. In our prior study of 47 consecutive subjects with ONH, the prevalence of endocrinopathies was 72%.
Currently there are no good clinical or biochemical markers that accurately predict which children will develop endocrinopathies in the backdrop of ONH. The presence of an endocrinopathy in our prior study was not associated with any radiological abnormalities and, thus, neuroimaging cannot be used to predict hypopituitarism in children with ONH [4] . Hypopituitarism can develop at any time in the first years of life and is usually diagnosed by either the presence of symptoms (later in the disease course) or by screening tests done at the discretion of the treating physician. Thus, patients with ONH may experience the health consequences of a hormonal abnormality before it is diagnosed and treated, highlighting the need for a better prognostic strategy in these children.
Hypothalamic dysfunction may also manifest as obesity. In a prior study, 44% of subjects with ONH had a body mass index (BMI) 6 85th percentile at age 5 years [4] . Obesity may be attributed to hypothalamic dysfunction involving the appetite/satiety centers of the lateral hypothalamic and ventromedial nuclei. In addition, the obesity has been ascribed to associated endocrinopathies such as growth hormone (GH) deficiency and/or hypothyroidism. Vision impairment and/or developmental delay may also contribute to the high prevalence of obesity in children with ONH [9, 10] . It is not known if markers for hypothalamic dysfunction could serve as predictors of obesity in children with ONH.
Mild hyperprolactinemia can occur in subjects with hypothalamic and/or pituitary stalk dysfunction [11] , and is often seen in subjects with ONH [4, 6] . Markedly elevated prolactin levels, seen in patients with prolactinomas, have been associated with weight gain and obesity in both adults [12] [13] [14] and children [15, 16] . There have been many proposed mechanisms to attempt to explain these findings, such as decreased dopaminergic tone and leptin resistance [13, 17] , but the pathophysiology remains unclear. There are no large studies investigating the relationship between mild hyperprolactinemia and either hypothalamic dysfunction and/or obesity in children with ONH.
The aims of this study were to examine whether elevated serum prolactin levels measured prior to age 3 years are a marker of hypopituitarism and/or obesity (BMI 6 85th percentile) in children with ONH using prospectively collected data.
Methods
An ONH registry was established in 1992 to collect prospective ophthalmic, endocrinological, and neuropsychological data on subjects with ONH. Clinical data from 262 subjects comprise this ongoing database and include comprehensive endocrine testing at the time of study enrollment ( ^ 36 months) (including measurements of prolactin, IGF-I, IGFBP-3, cortisol, TSH, and free thyroxine); additional endocrine data collected from subjects' treating endocrinologists, and repeat thyroid function testing and glucagon GH stimulation testing. Subjects are followed in this registry until age 5 years. The details of the study methodology of this registry are described elsewhere [4, 5] . The study was approved by the Children's Hospital Los Angeles Committee on Clinical Investigations.
Registry data on serum prolactin levels, endocrinological and auxological outcomes, and neuroradiographic findings were abstracted for this study. Subjects with an initial serum prolactin level through 2008 and known pituitary status (either hypopituitarism diagnosed at any time or confirmed normal pituitary hormones at age 5) were included. Serum prolactin levels were measured at or before the initial study visit ( ^ 3 years), and, if done at the initial study visit, were obtained under sedation with chloral hydrate. In addition, recent subjects have had repeat measurements of prolactin levels at the time of their glucagon stimulation test or at the discretion of their primary endocrinologist. Referral laboratories and assays used for analyses varied depending on whether the laboratory tests were drawn as part of a study visit or by the primary endocrinologist. Thus, hyperprolactinemia was defined as above the upper limit of the laboratory-defined normal range for age. Hypopituitarism was defined as either being prescribed hormone replacement (GH, levothyroxine, hydrocortisone, and/or desmopressin) and/or having a subnormal stimulated peak serum GH level ( ! 10 ng/ml after glucagon).
Auxological data were collected at annual study visits. BMI was calculated from the last available height and weight measurements in the database, and converted to standard deviation scores (SDS) using Epi Info Version 3.5.3 (a software program that calculates SDS using the 2000 Center for Disease Control growth references) [18] . Using the guidelines of the Center for Disease Control, overweight was defined as a BMI between the 85th and 95th percentiles ( 6 1.4 SDS) and obesity was defined as a BMI 6 95th percentile ( 6 2.1 SDS).
Data were analyzed using Stata 11.0 (College Station, Tex., USA) to examine the association of initial serum prolactin with documented pituitary status and BMI SDS. Summary statistics were used, with median values and 5th and 95th percentiles if not normally distributed. Comparisons between groups were performed by the 2 and Student's t test, or, if continuous variables, by Pearson's correlation. The non-parametric analogs were used when appropriate. Odds ratios (OR) and the 95% confidence intervals (CI) were estimated using logistic regression. Statistical significance was defined as an ␣ of 0.05, with two-sided alternative hypotheses.
Results
Demographic and clinical characteristics of the sample are presented in table 1 . Of the 125 subjects with an available initial serum prolactin level (measured at age 13.2 8 9.3 months), 73% had an elevated value, 41.6 8 21.1 ng/ml, and 27% had a normal value, 12.1 8 4.5 ng/ ml (p ! 0.001). Hyperprolactinemia was not associated with an absent septum pellucidum or hypoplastic corpus callosum. Subjects with an elevated initial prolactin level were more likely to have hypopituitarism (OR 2.45; 95% CI 1.10, 5.48). The association was driven primarily by GH deficiency (OR 2.63; 95% CI 1.14, 6.06), as there were no significant associations with other types of pituitary deficiencies: hypothyroidism (p = 0.360) and adrenal insufficiency (p = 0.574). A repeat prolactin level at an older age (44.4 8 20.1 months) was available in 52.8% of subjects. Prolactin levels remained normal in all subjects with a normal initial prolactin level (n = 12), and normalized in 61% (33/54) of subjects with an initially elevated prolactin level. There was no difference in the initial prolactin levels between those with persistent hyperprolactinemia (38.8 8 14.8 ng/ml) and those that normalized (39.3 8 16.7 ng/ml; p = 0.916). Subjects with persistent hyperprolactinemia were more likely to have hypopituitarism (81 vs. 55%; p = 0.048) and GHD (76 vs. 50%; p = 0.05) than those that normalized.
BMI data at age 5 years (59.6 8 5.5 months) were available for 112 subjects (89%); 31% were overweight and 20% were obese. Obesity did not correlate with elevated initial prolactin (p = 0.439); there was no association among those with (p = 0.715) and without (p = 1.00) GH deficiency. The median BMI SDS was higher among subjects with an elevated initial prolactin (1.01; -1.25, 3.26) compared to those with a normal prolactin (0.39; -1.1, 2.82), although this only approached statistical significance (p = 0.091). Persistent hyperprolactinemia was not associated with BMI SDS (p = 0.589). There was a statistically significant difference in the median BMI SDS between those with (1.14; -1.25, 3.26) and without GH deficiency (0.39; -1.1, 2.59) (p = 0.010).
Discussion
Hypopituitarism and obesity occur frequently in children with ONH, and currently it is difficult to predict which children with ONH will develop these co-morbidities. It is generally accepted that hyperprolactinemia is a marker of interrupted signaling between the hypothalamus and pituitary, but this is the first study to demonstrate that elevated initial serum prolactin levels may be a potential marker for hypopituitarism in children with ONH.
Hypopituitarism was least common among those with an initially normal serum prolactin level (44%; n = 15/34). The prevalence of hypopituitarism was higher (66%) among those with an initially elevated prolactin, corresponding to a 2.5-fold increased likelihood of hypopituitarism. The prevalence of hypopituitarism was highest (81%) for those with a persistently elevated prolactin. An elevated serum prolactin was specific to GH deficiency in this study, which likely reflects the predominance of GH deficiency in ONH.
This study confirms the high prevalence of obesity (20%) at age 5 years in children with ONH, which is notably higher than the national reported prevalence of 10.4% (p ! 0.001) in children ages 2-5 years (NHANES 2007-2008) [19] . While obesity did not correlate with early hyperprolactinemia, the observed higher median BMI SDS between those with and without early hyperprolactinemia (1.0 vs. 0.4; p = 0.09) is still of clinical significance and also suggestive of underlying hypothalamic dysfunction. The increased BMI and prevalence of obesity are clearly concerning for future health implications.
Thirty-four percent of subjects with elevated initial prolactin levels did not have hypopituitarism. The young age of participants precluded the detection of hypopituitarism presenting later in life, for example, during puberty. Additionally, assessment of gonadotropin deficiency was not possible due to the young age of our subjects and absence of laboratory data from the mini-puberty of infancy [20] . Therefore, our prevalence of hypopituitarism may be an underestimation. There is the potential for false elevation of prolactin levels attributable to, for example, stress and sleep. Moreover, prolactin levels were collected under non-standardized conditions, were sent to different laboratories, and were measured using multiple assay methodologies, all of which may have affected their results. Prolactin levels are normally higher in the first few months of life, but decline to normal childhood values by 3 months of age. This was an unlikely source of bias since only 1 of our subjects had prolactin levels checked prior to 3 months of age. A repeat serum prolactin level was not available for 48% of our study sample. Repeat measurements became more frequent over the past 7 years, and were generally obtained at the time of the glucagon stimulation test performed as part of the registry. Subjects were less likely to have a repeat prolactin obtained if they were already receiving GH replacement therapy. The majority of these subjects had an elevated initial prolactin, therefore the exclusion of these subjects from the subset analysis of repeat prolactin levels may have led to the underestimation of the association of prolactin levels with endocrinological and auxological outcomes.
In conclusion, early serum prolactin levels are often elevated in children with ONH. There is an association between early hyperprolactinemia and GH deficiency, but not other pituitary deficiencies, by age 5 years. However, there were also many subjects with normal early serum prolactin levels who subsequently developed hypopituitarism, indicating that screening for hypopituitarism is necessary regardless of early prolactin levels. Further studies are needed to identify possible clinical and/or biochemical markers that could be used to predict hypopituitarism in children with ONH. Until then, it is important to screen these patients regularly for pituitary hormone deficiencies.
